Rafferty Asset Management LLC Increases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Rafferty Asset Management LLC increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,860 shares of the medical research company’s stock after purchasing an additional 360 shares during the period. Rafferty Asset Management LLC’s holdings in Charles River Laboratories International were worth $1,266,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. D1 Capital Partners L.P. acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth approximately $172,752,000. Norges Bank acquired a new stake in Charles River Laboratories International during the fourth quarter worth $98,886,000. Wellington Management Group LLP raised its position in Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock valued at $752,508,000 after purchasing an additional 335,658 shares during the period. Nomura Holdings Inc. acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at $56,820,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth about $42,776,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm’s stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on CRL. Evercore ISI raised shares of Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 target price on the stock in a research report on Thursday, May 8th. Cowen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, May 14th. Barclays increased their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 8th. TD Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price on the stock in a research report on Wednesday, May 14th. Finally, Morgan Stanley decreased their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $172.31.

Charles River Laboratories International Price Performance

CRL stock opened at $135.01 on Thursday. The business’s 50-day moving average is $133.64 and its two-hundred day moving average is $164.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The firm has a market capitalization of $6.63 billion, a P/E ratio of 900.08, a P/E/G ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period in the prior year, the firm earned $2.27 earnings per share. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).